Skip to content
DataLookout
Menu

Lumiteg-RNCT07885566

RWS of PDT for CIN 2

StatusNot Yet Recruiting
PhaseNot specified
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Pathological Remission Rate at 6 Months
Timeframe: 6 months after the initial PDT treatment

Secondary (4)

HPV Clearance Rate at 3 Months
HPV Clearance Rate at 6 Months
Incidence and Severity of Treatment-Related Adverse Events
Pathological Remission Rate at 12 Months

Arms and interventions

CIN2 patients receiving routine clinical PDT

This cohort consists of female patients aged 18-50 years with histopathologically confirmed cervical intraepithelial neoplasia grade 2 (CIN2) and positive HPV test. All participants receive photodynamic therapy (PDT) approved for CIN2 in routine clinical practice. The decision to administer PDT, as well as treatment times and intervals, are determined by attending clinicians according to product instructions and clinical conditions, not mandated by this study protocol. Baseline and follow-up assessments including TCT, HPV testing, colposcopy-guided biopsy and HPV integration testing will be performed as specified in the study to evaluate real-world effectiveness and safety of PDT.

Combination products: Hexaminolevulinate (HAL)